Q4 FY26 results analysis · May 22, 2026

Fortis Healthcare Q4 FY26 Results Analysis: PAT Surges 44.6%, EBITDA Margin Expands 214 bps

+44.6%PAT year on year, Rs. 271.19 Cr
Cofacto ResearchPublished May 22, 20262 min readPositive read
Quick summary

Fortis Healthcare Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 2,364.67 Cr (+17.84% YoY) and PAT growth of +44.58% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 22, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 2,364.67 Cr (+17.84% YoY)
PAT (Q4)Rs. 271.19 Cr (+44.58% YoY)
EBITDA margin22.70% (+214 bps YoY)
EPS (Q4)Rs. 3.52 (+44.26% YoY)
Market capRs. 72,630.64 Cr
CMPRs. 961.80

Quarter Snapshot

Consolidated revenue grew 17.8% YoY, PAT surged 44.6% YoY, and FY26 EBITDA margin expanded 214 bps to 23.40% from operating leverage. Diagnostics margin nearly doubled, but finance costs rose 70% from acquisition debt and occupancy remains below target, with key legal overhang pending September 2026.

Key Investment Insights

Key Positives

  • Consolidated PAT attributable to owners grew 44.58% YoY to Rs.26,585 Lakh in Q4 FY26.
  • FY26 EBITDA margin expanded 214 bps to 23.40%, driven by total expenses growing slower than revenue.
  • Diagnostics segment EBIT margin expanded 649 bps YoY to 15.84% in FY26.
  • Healthcare segment EBIT grew 30.13% YoY in FY26 to Rs.139,370 Lakh with margin expansion of 180 bps.
  • Operating cash flow was 150% of PAT, indicating high earnings quality.
  • Credit rating upgraded by CRISIL from AA to AA+ (Stable).

Risk Factors

  • Occupancy declined to 67% in Q3 FY26 due to new facility ramp-up; Q4 occupancy data not disclosed.
  • Current ratio at 0.86x indicates working capital pressure from rapid expansion.
  • Tax disputes total Rs.266 Cr (demands for AY 2021-22 and AY 2024-25); company evaluating appeals.
  • Legal uncertainty from NTK vs Daiichi Sankyo judgment due September 10, 2026.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.